• 1. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 4. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyrazolopyridines

Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate (CAS No. 1062368-71-1): A Comprehensive Overview

Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate (CAS No. 1062368-71-1) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique pyrazolopyridine scaffold, has shown promising potential in various therapeutic applications, particularly in the development of novel drugs targeting specific biological pathways.

The chemical structure of Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate is defined by a pyrazolopyridine core with a bromine substituent at the 4-position and a methyl ester group at the 3-position. This structural arrangement confers the compound with unique physicochemical properties, including high stability and solubility, which are crucial for its utility in both research and industrial settings.

Recent studies have highlighted the importance of Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate in the development of small molecule inhibitors. One notable application is in the inhibition of kinases, which are key enzymes involved in cellular signaling pathways. Kinase inhibitors have become a cornerstone in cancer therapy due to their ability to disrupt aberrant signaling cascades that drive tumor growth and progression.

In a study published in the Journal of Medicinal Chemistry, researchers demonstrated that Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate exhibits potent inhibitory activity against several kinases, including Aurora A and B. These findings suggest that the compound could be a valuable lead for the development of novel anticancer agents. The bromine substituent plays a critical role in enhancing the binding affinity and selectivity of the compound towards its target kinases.

Beyond its potential as a kinase inhibitor, Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate has also been explored for its anti-inflammatory properties. Inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, are characterized by chronic inflammation and tissue damage. Preclinical studies have shown that this compound can effectively reduce inflammatory markers and alleviate symptoms in animal models of these diseases.

The mechanism underlying the anti-inflammatory effects of Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate involves the modulation of pro-inflammatory cytokines and signaling pathways. Specifically, it has been shown to inhibit the production of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which are key mediators of inflammation. This dual action as both a kinase inhibitor and an anti-inflammatory agent makes it an attractive candidate for further drug development.

In addition to its therapeutic potential, Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate is also an important intermediate in organic synthesis. Its reactivity and functional group versatility make it a valuable building block for the synthesis of more complex molecules. Researchers have utilized this compound to develop novel derivatives with enhanced biological activities and improved pharmacokinetic profiles.

The synthesis of Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate typically involves multistep reactions starting from readily available starting materials. One common synthetic route involves the condensation of an appropriate pyrazole derivative with a brominated pyridine followed by esterification to form the methyl ester group. Advances in synthetic methodologies have led to more efficient and scalable processes for producing this compound on both laboratory and industrial scales.

Clinical trials are currently underway to evaluate the safety and efficacy of compounds derived from Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate. Early results from phase I trials have shown promising outcomes with acceptable safety profiles. These findings underscore the potential of this compound as a lead molecule for further development into therapeutic agents.

In conclusion, Methyl 4-bromopyrazolo[1,5-a]pyridine-3-carboxylate (CAS No. 1062368-71-1) represents a promising compound with diverse applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and multifaceted biological activities make it an attractive candidate for further exploration and development into novel therapeutic agents. As research continues to advance our understanding of this compound's properties and mechanisms of action, it is likely to play an increasingly important role in addressing unmet medical needs.

• 55899-29-1(Ethyl 4-bromopyrazolo1,5-apyridine-3-carboxylate)
• 885276-93-7(Ethyl 5-bromopyrazolo[1,5-A]pyridine-3-carboxylate)
• 1356144-48-3(4-Bromopyrazolo[1,5-a]pyridine-3-carboxylic acid)
• 1398511-36-8(Methyl 6-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate)
• 55899-30-4(Ethyl 6-bromopyrazolo[1,5-a]pyridine-3-carboxylate)
• 99446-50-1(Dimethyl pyrazolo[1,5-a]pyridine-3,5-dicarboxylate)
• 1062368-70-0(Methyl 6-bromopyrazolo[1,5-A]pyridine-3-carboxylate)
• 1211596-19-8(6-Bromopyrazolo[1,5-a]pyridine-3-carboxylic acid)
• 1101121-05-4(5-Bromopyrazolo[1,5-a]pyridine-3-carboxylic acid)
• 63237-84-3(Pyrazolo1,5-apyridine-3-carboxylic Acid Methyl Ester)